Law and Regulations

Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.

Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.

At AAP 2025, Ron Friedman discussed best practices for responding to a DEA inspection, how to identify any red flags, and best practices for dispensing.

A conversation with Rob Frankil, RPh, executive director of the Philadelphia Association of Retail Druggists.

Explore key legislative actions changing pharmacy practice in 2025 and beyond.

Senators Elizabeth Warren and Tina Smith have reintroduced the Pharmaceutical Supply Chain Defense and Enhancement Act originally established in 2020.

Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.

The Affordable Care Act was passed in 2010 to make health care and prescription medicine more accessible. Did it succeed?

Pharmacy experts from AON Pharmacy in Florida discussed the Inflation Reduction Act and how it affects reimbursement for Medicare Part D drugs.

Pharmacy law experts detailed the Drug Supply Chain Security Act, highlighting the role each entity within the supply chain plays in ensuring the safety and authenticity of US prescription drugs.

The Drug Enforcement Administration gives controlled substance licenses, and can just as easily take them away.

Current rules governing lawsuits must be revisited to strike a balance between legitimate and frivolous legal actions against health care providers.

The 70-plus-page lawsuit is directed at Express Scripts for its dealings with drug manufacturers in fueling the US opioid crisis.

Following the Federal Trade Commission’s interim report on PBMs, legislators are galvanized to make change happen.

The health care giant’s pharmacy benefit manager subsidiary filed a lawsuit claiming that the FTC’s recent 6(b) report was false and misleading.

McKesson, Cardinal Health, and Cencora will share the settlement payment, resolving claims that the companies were significantly involved in fueling the US opioid epidemic.

New prices will go into effect on January 1, 2026, for individuals covered by Medicare Part D prescription drugs.

Our congressional representatives have plenty of interaction with PBM lobbyists. It’s time they hear from patients as well.

An interim FTC report outlined how the rise of vertical integration and concentration has led to devastating results for both patients and fragile pieces of the health care delivery system.

Industry experts explored the increase in US prescription drug spending and how state spending targets come into play regarding patients’ rising out-of-pocket costs.

A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.

See what's trending in pharmacy with a preview of the Total Pharmacy April issue.

This week, a divided America watched as the Supreme Court heard oral arguments regarding whether to reinstate restrictions on accessing mifepristone, an essential drug used in medication abortion.